

# Hemophilia Drugs-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/H9893331E658EN.html>

Date: May 2018

Pages: 147

Price: US\$ 2,480.00 (Single User License)

ID: H9893331E658EN

## Abstracts

### Report Summary

Hemophilia Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Hemophilia Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Hemophilia Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Hemophilia Drugs worldwide, with company and product introduction, position in the Hemophilia Drugs market

Market status and development trend of Hemophilia Drugs by types and applications

Cost and profit status of Hemophilia Drugs, and marketing status

Market growth drivers and challenges

The report segments the global Hemophilia Drugs market as:

Global Hemophilia Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Hemophilia Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Hemophilia A

Hemophilia B

Hemophilia C

Global Hemophilia Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinic

Hospital

Global Hemophilia Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Hemophilia Drugs Sales Volume, Revenue, Price and Gross Margin):

Baxalta

Bayer

CSL Behring

Novo Nordisk

Pfizer

Roche

Alnylam Pharmaceuticals

Amarna Therapeutics

Asklepios BioPharmaceutical

Biogen

BioMarin

Catalyst Bioscience

Chiesi Farmaceutici

Dimension Therapeutics

Emergent BioSolutions

Grifols, Kedrion Biopharma

Octapharma

rEVO Biologics

OPKO Biologics

Sangamo Biosciences

Spark Therapeutics

Swedish Orphan Biovitrum

In a word, the report provides detailed statistics and analysis on the state of the

industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF HEMOPHILIA DRUGS**

- 1.1 Definition of Hemophilia Drugs in This Report
- 1.2 Commercial Types of Hemophilia Drugs
  - 1.2.1 Hemophilia A
  - 1.2.2 Hemophilia B
  - 1.2.3 Hemophilia C
- 1.3 Downstream Application of Hemophilia Drugs
  - 1.3.1 Clinic
  - 1.3.2 Hospital
- 1.4 Development History of Hemophilia Drugs
- 1.5 Market Status and Trend of Hemophilia Drugs 2013-2023
  - 1.5.1 Global Hemophilia Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Hemophilia Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Hemophilia Drugs 2013-2017
- 2.2 Production Market of Hemophilia Drugs by Regions
  - 2.2.1 Production Volume of Hemophilia Drugs by Regions
  - 2.2.2 Production Value of Hemophilia Drugs by Regions
- 2.3 Demand Market of Hemophilia Drugs by Regions
- 2.4 Production and Demand Status of Hemophilia Drugs by Regions
  - 2.4.1 Production and Demand Status of Hemophilia Drugs by Regions 2013-2017
  - 2.4.2 Import and Export Status of Hemophilia Drugs by Regions 2013-2017

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Production Volume of Hemophilia Drugs by Types
- 3.2 Production Value of Hemophilia Drugs by Types
- 3.3 Market Forecast of Hemophilia Drugs by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Hemophilia Drugs by Downstream Industry
- 4.2 Market Forecast of Hemophilia Drugs by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HEMOPHILIA DRUGS**

5.1 Global Economy Situation and Trend Overview

5.2 Hemophilia Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 6 HEMOPHILIA DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

6.1 Production Volume of Hemophilia Drugs by Major Manufacturers

6.2 Production Value of Hemophilia Drugs by Major Manufacturers

6.3 Basic Information of Hemophilia Drugs by Major Manufacturers

6.3.1 Headquarters Location and Established Time of Hemophilia Drugs Major Manufacturer

6.3.2 Employees and Revenue Level of Hemophilia Drugs Major Manufacturer

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 HEMOPHILIA DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Baxalta

7.1.1 Company profile

7.1.2 Representative Hemophilia Drugs Product

7.1.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Baxalta

7.2 Bayer

7.2.1 Company profile

7.2.2 Representative Hemophilia Drugs Product

7.2.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Bayer

7.3 CSL Behring

7.3.1 Company profile

7.3.2 Representative Hemophilia Drugs Product

7.3.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of CSL Behring

7.4 Novo Nordisk

7.4.1 Company profile

7.4.2 Representative Hemophilia Drugs Product

7.4.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk

## 7.5 Pfizer

7.5.1 Company profile

7.5.2 Representative Hemophilia Drugs Product

7.5.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Pfizer

## 7.6 Roche

7.6.1 Company profile

7.6.2 Representative Hemophilia Drugs Product

7.6.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Roche

## 7.7 Alnylam Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative Hemophilia Drugs Product

7.7.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Alnylam

## Pharmaceuticals

## 7.8 Amarna Therapeutics

7.8.1 Company profile

7.8.2 Representative Hemophilia Drugs Product

7.8.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Amarna

## Therapeutics

## 7.9 Asklepios BioPharmaceutical

7.9.1 Company profile

7.9.2 Representative Hemophilia Drugs Product

7.9.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Asklepios

## BioPharmaceutical

## 7.10 Biogen

7.10.1 Company profile

7.10.2 Representative Hemophilia Drugs Product

7.10.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Biogen

## 7.11 BioMarin

7.11.1 Company profile

7.11.2 Representative Hemophilia Drugs Product

7.11.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of BioMarin

## 7.12 Catalyst Bioscience

7.12.1 Company profile

7.12.2 Representative Hemophilia Drugs Product

7.12.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Catalyst

## Bioscience

## 7.13 Chiesi Farmaceutici

7.13.1 Company profile

7.13.2 Representative Hemophilia Drugs Product

- 7.13.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Chiesi Farmaceutici
- 7.14 Dimension Therapeutics
  - 7.14.1 Company profile
  - 7.14.2 Representative Hemophilia Drugs Product
  - 7.14.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Dimension Therapeutics
- 7.15 Emergent BioSolutions
  - 7.15.1 Company profile
  - 7.15.2 Representative Hemophilia Drugs Product
  - 7.15.3 Hemophilia Drugs Sales, Revenue, Price and Gross Margin of Emergent BioSolutions
- 7.16 Grifols, Kedrion Biopharma
- 7.17 Octapharma
- 7.18 rEVO Biologics
- 7.19 OPKO Biologics
- 7.20 Sangamo Biosciences
- 7.21 Spark Therapeutics
- 7.22 Swedish Orphan Biovitrum

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HEMOPHILIA DRUGS**

- 8.1 Industry Chain of Hemophilia Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HEMOPHILIA DRUGS**

- 9.1 Cost Structure Analysis of Hemophilia Drugs
- 9.2 Raw Materials Cost Analysis of Hemophilia Drugs
- 9.3 Labor Cost Analysis of Hemophilia Drugs
- 9.4 Manufacturing Expenses Analysis of Hemophilia Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF HEMOPHILIA DRUGS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing

- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference



## I would like to order

Product name: Hemophilia Drugs-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/H9893331E658EN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H9893331E658EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970